These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31107292)

  • 1. Prospects for pharmacotherapies to treat alcohol use disorder: an update on recent human studies.
    Farokhnia M; Browning BD; Leggio L
    Curr Opin Psychiatry; 2019 Jul; 32(4):255-265. PubMed ID: 31107292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GABAB Agonists for the Treatment of Alcohol Use Disorder.
    Mirijello A; Caputo F; Vassallo G; Rolland B; Tarli C; Gasbarrini A; Addolorato G
    Curr Pharm Des; 2015; 21(23):3367-72. PubMed ID: 26088121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.
    Litten RZ; Wilford BB; Falk DE; Ryan ML; Fertig JB
    Subst Abus; 2016; 37(2):286-98. PubMed ID: 26928397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
    Burnette EM; Nieto SJ; Grodin EN; Meredith LR; Hurley B; Miotto K; Gillis AJ; Ray LA
    Drugs; 2022 Feb; 82(3):251-274. PubMed ID: 35133639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.
    Fischler PV; Soyka M; Seifritz E; Mutschler J
    Front Pharmacol; 2022; 13():927703. PubMed ID: 36263121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
    Castrén S; Mäkelä N; Alho H
    Curr Opin Psychiatry; 2019 Jul; 32(4):266-274. PubMed ID: 30973369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators].
    Agabio R; Colombo G
    Psychiatr Pol; 2015; 49(2):215-23. PubMed ID: 26093587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of GABA
    Maccioni P; Colombo G
    CNS Drugs; 2019 Feb; 33(2):107-123. PubMed ID: 30604283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment.
    Farokhnia M; Sheskier MB; Lee MR; Le AN; Singley E; Bouhlal S; Ton T; Zhao Z; Leggio L
    Neuropharmacology; 2018 Jul; 137():230-239. PubMed ID: 29665351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of medications for alcohol-use disorders targeting the GABAB receptor system.
    Agabio R; Maccioni P; Carai MA; Gessa GL; Froestl W; Colombo G
    Recent Pat CNS Drug Discov; 2012 Aug; 7(2):113-28. PubMed ID: 22574677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttraumatic Stress Disorder and Alcohol Use Disorder: A Critical Review of Pharmacologic Treatments.
    Petrakis IL; Simpson TL
    Alcohol Clin Exp Res; 2017 Feb; 41(2):226-237. PubMed ID: 28102573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
    Williams EC; Matson TE; Harris AHS
    Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies.
    Morley KC; Perry CJ; Watt J; Hurzeler T; Leggio L; Lawrence AJ; Haber P
    Expert Opin Pharmacother; 2021 Jul; 22(10):1291-1303. PubMed ID: 33615945
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacotherapy of alcoholism - an update on approved and off-label medications.
    Soyka M; Müller CA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1187-1199. PubMed ID: 28658981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial.
    Hauser P; Fuller B; Ho SB; Thuras P; Kern S; Dieperink E
    Addiction; 2017 Jul; 112(7):1173-1183. PubMed ID: 28192622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noradrenergic targets for the treatment of alcohol use disorder.
    Haass-Koffler CL; Swift RM; Leggio L
    Psychopharmacology (Berl); 2018 Jun; 235(6):1625-1634. PubMed ID: 29460163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinic receptor modulation to treat alcohol and drug dependence.
    Rahman S; Engleman EA; Bell RL
    Front Neurosci; 2014; 8():426. PubMed ID: 25642160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Placebo-controlled, Clinical Trial of Prazosin for the Treatment of Alcohol Use Disorder.
    Wilcox CE; Tonigan JS; Bogenschutz MP; Clifford J; Bigelow R; Simpson T
    J Addict Med; 2018; 12(5):339-345. PubMed ID: 29664896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discriminative stimulus effects of flumazenil: perceptual masking by baclofen, and lack of substitution with gamma-hydroxybutyrate and its precursors 1,4-butanediol and gamma-butyrolactone.
    Koek W; Carter LP; Wu H; Coop A; France CP
    Behav Pharmacol; 2006 May; 17(3):239-47. PubMed ID: 16572002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam.
    Krupitsky EM; Rudenko AA; Burakov AM; Slavina TY; Grinenko AA; Pittman B; Gueorguieva R; Petrakis IL; Zvartau EE; Krystal JH
    Alcohol Clin Exp Res; 2007 Apr; 31(4):604-11. PubMed ID: 17374039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.